{
    "nct_id": "NCT06047886",
    "official_title": "Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS",
    "inclusion_criteria": "1. AML in morphologic remission with intermediate/high-risk features or relapsed disease 1 or 2\n2. ALL in morphologic remission with high-risk features or relapsed disease 1 or 2\n3. Lymphoid malignancies in CR or PR (e.g. non-Hodgkin's lymphoma, prolymphocytic leukemia, CLL)\n4. Myelodysplastic syndromes with <=10% blasts\n5. CML in morphologic remission after blast phase or accelerated phase\n6. Primary myelofibrosis with <=10% blasts ^morphologic remission is defined as <5% blasts on the bone marrow biopsy. Negative test for donor-specific antibody within 28 days of starting conditioning regimen, or adequate for standard desensitization protocol.\nHealthy volunteers allowed\nMust have minimum age of 4 Weeks\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Non-compliant patients.\n2. No appropriate caregivers identified.\n3. Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).\n4. Patients with known allergy to DMSO.\n5. Pregnant or breastfeeding women",
    "miscellaneous_criteria": ""
}